VLS Valneva SE

VALNEVA: Declaration of shares and voting rights - Interim status at November 2, 2021 (and information at October 31, 2021)

VALNEVA: Declaration of shares and voting rights - Interim status at November 2, 2021 (and information at October 31, 2021)

VALNEVA

Declaration of shares and voting rights

Interim status at November 2, 2021 (and information at October 31, 2021)

__________________________________________________________________________________________

Company name: VALNEVA

Registered office: 6 rue Alain Bombard, 44800 Saint-Herblain (France)

Regulated market of Euronext Paris - Compartment B

Declaration date: November 4, 2021

Interim status at November 2, 2021

Number of shares

composing the share capital of Valneva
Total number of voting rights including suspended voting rights*Description of the changeDate on which this change was recognizedTotal number of voting rights excluding suspended voting rights**
 



105,086,163



 



    including:
  • 105,065,649 ordinary shares with a par value of €0.15 each; and
  • 20,514 preferred shares convertible into ordinary shares, with a par value of €0.15 each
127,763,819 



Double voting rights granted on 10,000 ordinary shares



 



Capital increase without preferential subscription rights (5,175,000 new ordinary shares issued)



 



 
 



 



November 1, 2021   









 November 2, 20211





127,639,497

Information at October 31, 2021

Number of shares

composing the share capital of Valneva
Total number of voting rights including suspended voting rights*Description of the changeDate on which this change was recognizedTotal number of voting rights excluding suspended voting rights**
99,911,163



 



    including:
  • 99,890,649 ordinary shares with a par value of €0.15 each ; and
  • 20,514 preferred shares convertible into ordinary shares, with a par value of €0.15 each
122,578,819Transfer of 3,300 shares with double voting rights



 



Cancellation of 4,025 ordinary shares held as treasury shares



 



Transfer of 6,333 shares with double voting rights into bearer form



 



Transfer of 150 ordinary shares into bearer form






October 1, 2021  



 



October 4, 2021 



 



Between October 4 and October 6, 2021 



 



October 23, 2021





122,454,497




1 Management Board decisions of October 28 and October 30, 2021, Settlement and delivery of shares on November 2, 2021.

* Theoretical voting rights. This number is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on the basis of all shares to which voting rights are attached, including those for which voting rights have been suspended.

In accordance with the Company's Articles of Association, the transfer into double voting rights of part of the ordinary shares took place as from May 28, 2015.

** Net (or exercisable at a General Meeting) voting rights.

Attachment



EN
04/11/2021

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Valneva SE

 PRESS RELEASE

Valneva annonce sa participation à des conférences investisseurs

Valneva annonce sa participation à des conférences investisseurs  Lyon (France), le 2 mars 2026 – (Nasdaq: VALN; Euronext Paris: VLA), société spécialisée dans les vaccins, a annoncé aujourd'hui que des membres de son équipe dirigeante feront des présentations et participeront à des rendez-vous avec des investisseurs institutionnels lors de prochaines conférences aux États-Unis et en Europe. Thomas Lingelbach, directeur général, et Peter Bühler, directeur financier, feront un point sur les principaux éléments de création de valeur de la Société ainsi que les catalyseurs attendus, dont les...

 PRESS RELEASE

Valneva to Participate in Upcoming Investor Conferences

Valneva to Participate in Upcoming Investor Conferences Lyon (France), March 2, 2026 – (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced its senior management will present and meet with investors at upcoming investor conferences in the United States and Europe. CEO Thomas Lingelbach and CFO Peter Buhler will discuss the Company’s key value drivers and upcoming catalysts, including the topline Phase 3 data readout for VLA15, the Company’s Lyme disease vaccine candidate, which partner Pfizer expects to report in the first half of 2026. The TD Cowen presenta...

Martial Descoutures
  • Martial Descoutures

ResearchPool Subscriptions

Get the most out of your insights

Get in touch